<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541772</url>
  </required_header>
  <id_info>
    <org_study_id>OOS-CANCER-1</org_study_id>
    <nct_id>NCT03541772</nct_id>
  </id_info>
  <brief_title>Evaluation of Oncoxin-Viusid® in Head and Neck Cancer</brief_title>
  <official_title>&quot;Combined Oncoxin-Viusid® Treatment With Radiotherapy and Chemotherapy in Patients With Head and Neck Cancer. Phase II, Randomized and Double-blind Study&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nutritional supplements containing antioxidants seem to decrease toxicity associated with
      Radiotherapy (RT) and Chemotherapy (CT) in patients with malignant head and neck tumors.
      Oncoxin-Viusid® (OV) is a nutritional supplement with antioxidant, immunomodulator and
      antitumor effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective

      To assess the efficacy and safety of OV in patients with head and neck tumors during
      treatment with radio-chemotherapy.

      Materials and Methods

      Patients diagnosed with Head and Neck Carcinoma, and indicated to follow a radiotherapy
      treatment concurrent with Radiosensitizing Chemotherapy, were included in a phase II,
      randomized, prospective, controlled and double-blind study in two treatment arms: RT + CT +
      Placebo (n = 30) and RT + CT + OV (n = 30) during one year in a tertiary center (INOR), with
      the aim of evaluating the reduction of toxicities of RT-CT and improve the quality of life of
      patients during these oncospecific treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2015</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease the degrees of toxicities of Radiotherapy and Chemotherapy</measure>
    <time_frame>4 months</time_frame>
    <description>Tumor biopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease the degrees of toxicities of Radiotherapy and Chemotherapy</measure>
    <time_frame>4 months</time_frame>
    <description>Biochemical analysis of urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease the degrees of toxicities of Radiotherapy and Chemotherapy</measure>
    <time_frame>4 months</time_frame>
    <description>anamnesis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease the degrees of toxicities of Radiotherapy and Chemotherapy</measure>
    <time_frame>4 months</time_frame>
    <description>physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improve the quality of life of patients during radiotherapy</measure>
    <time_frame>4 months</time_frame>
    <description>Index of Karnofsky</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the therapeutic range of radiotherapy</measure>
    <time_frame>4 months</time_frame>
    <description>Kaplan-Meyer's Method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Head Cancer Neck</condition>
  <arm_group>
    <arm_group_label>Oncoxin-Viusid®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy + Chemotherapy + Oncoxin-viusid®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Radiotherapy + Chemotherapy + Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oncoxin-Viusid®</intervention_name>
    <description>Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments</description>
    <arm_group_label>Oncoxin-Viusid®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes

          -  over 18 years of age

          -  With histological diagnosis of carcinoma of the head and neck

          -  Regardless of the variety or degree of histological differentiation and clinical stage

          -  Tributaries of concomitant treatment with ionizing radiation and radiosensitizing
             chemotherapy with intercurrent diseases compensated and index of Karnofsky &gt; 59

          -  Acceptable hematological parameters

          -  Women not pregnant or lactating

          -  Who authorized their inclusion in the investigation, through their informed consent.

        Exclusion Criteria:

          -  Patients with a second concomitant primary tumor and / or contraindication to platinum
             chemotherapy

          -  Patients who are under another research protocol or who have decompensated psychiatric
             disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivonne Chon, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>INOR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Oncology and Radiobiology of Cuba</name>
      <address>
        <city>Vedado</city>
        <state>La Habana</state>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <reference>
    <citation>Marín Caro MM, Laviano A, Pichard C. Nutritional intervention and quality of life in adult oncology patients. Clin Nutr. 2007 Jun;26(3):289-301. Epub 2007 Mar 21. Review.</citation>
    <PMID>17368656</PMID>
  </reference>
  <reference>
    <citation>Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000 Oct 1;18(19):3339-45. Erratum in: J Clin Oncol 2000 Dec 15;18(24):4110-1.</citation>
    <PMID>11013273</PMID>
  </reference>
  <reference>
    <citation>Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):739-47.</citation>
    <PMID>11849797</PMID>
  </reference>
  <reference>
    <citation>Bardia A, Tleyjeh IM, Cerhan JR, Sood AK, Limburg PJ, Erwin PJ, Montori VM. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc. 2008 Jan;83(1):23-34. doi: 10.4065/83.1.23. Review.</citation>
    <PMID>18173999</PMID>
  </reference>
  <reference>
    <citation>Lamson DW, Brignall MS. Natural agents in the prevention of cancer, part two: preclinical data and chemoprevention for common cancers. Altern Med Rev. 2001 Apr;6(2):167-87. Review.</citation>
    <PMID>11302780</PMID>
  </reference>
  <reference>
    <citation>Márquez J, Mena J, Hernandez-Unzueta I, Benedicto A, Sanz E, Arteta B, Olaso E. Ocoxin® oral solution slows down tumor growth in an experimental model of colorectal cancer metastasis to the liver in Balb/c mice. Oncol Rep. 2016 Mar;35(3):1265-72. doi: 10.3892/or.2015.4486. Epub 2015 Dec 16.</citation>
    <PMID>26676882</PMID>
  </reference>
  <reference>
    <citation>Rodrigues MJ, Bouyon A, Alexandre J. [Role of antioxidant complements and supplements in oncology in addition to an equilibrate regimen: a systematic review]. Bull Cancer. 2009 Jun;96(6):677-84. doi: 10.1684/bdc.2009.0886. Review. French.</citation>
    <PMID>19493854</PMID>
  </reference>
  <reference>
    <citation>Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev. 1999 Oct;4(5):304-29. Review.</citation>
    <PMID>10559547</PMID>
  </reference>
  <reference>
    <citation>Lamson DW, Brignall MS. Antioxidants and cancer therapy II: quick reference guide. Altern Med Rev. 2000 Apr;5(2):152-63.</citation>
    <PMID>10767670</PMID>
  </reference>
  <reference>
    <citation>Mahdavi R, Faramarzi E, Seyedrezazadeh E, Mohammad-Zadeh M, Pourmoghaddam M. Evaluation of oxidative stress, antioxidant status and serum vitamin C levels in cancer patients. Biol Trace Elem Res. 2009 Jul;130(1):1-6. doi: 10.1007/s12011-008-8309-2. Epub 2009 Jan 17.</citation>
    <PMID>19148586</PMID>
  </reference>
  <reference>
    <citation>Hernandez-Unzueta I, Benedicto A, Olaso E, Sanz E, Viera C, Arteta B, Márquez J. Ocoxin oral solution(®) as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver. Oncol Lett. 2017 Jun;13(6):4002-4012. doi: 10.3892/ol.2017.6016. Epub 2017 Apr 10.</citation>
    <PMID>28599406</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head Carcinoma</keyword>
  <keyword>Neck Carcinoma</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Oncoxin Viusid</keyword>
  <keyword>Nutritional supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

